NanoViricides Inc. (NNVC)

[BonelessCat]

E-mail exchange as a follow up to Wednesday's presentation:

Hi Dr. Seymour,

Congratulations on a well constructed presentation in San Francisco. I
was wondering if you could address some questions posed from posters
on iHub?

--During the presentation, you specifically mentioned EKC, Flu, HSV
and HIV, but you didn't say anything about Dengue. Was there a reason
you didn't mention it?

Ran out of time. I'll build some dengue slides for the Puerto Rico conference
and will incorporate them into future presentations. I consider dengue a terrific opportunity. First of all,
we have world class collaborators. Secondly, I have not found any dengue drugs in active trials and I've been told that the Sanofi vaccine, if it gets approved, won't be available until 2017. Also, it's clearly an orphan drug and the potential for the priority review voucher upon approval makes dengue a very inviting target. In addition, the initial results out of Dr. Harris's lab were really quite good which means a minimal amount of tweaking will be necessary. Lastly, because there's no existing treatment, and no prospect of one in the near term, we've gotten excellent cooperation from our government connections.

--In your opening you talked about penicillin and how it destroyed the
surface of bacteria adding that nanoviricides do the same to bacteria.

Is it possible to equip a nanoviricide to go after bacteria? Is this
something NNVC might do in the future?

I've never looked into this because the anti-viral
market is on its way to becoming a $100B/year business. Plenty of opportunities there


--You also made a point of stating the company is acquiring a
manufacturing facility. That has been a goal for several years, but
you used the phrase "is acquiring." Is progress being made? Are you
closer to a deal, or is this still merely a goal?

I jumped the gun in saying that we've "acquired"
a manufacturing facility. In reality, we've identified a building, had it inspected by a structural engineer
and are awaiting some addition inspections before making the acquisition. This is the best candidate we've seen thus far


--When you said an INDA would be filed in the coming months, would
that be a few months or might that be better measured in longer terms.

What I said was that we would be filing for our pre-IND meeting in the coming months. That was also mentioned in the 10K. That is the first step towards filing an IND. At the meeting the FDA gives guidance as to what they want to see in the IND filing. Once we complete all those tasks, only then is an IND filed. Since I don't know now what those tasks will be, I can't give any estimates as to time

Incidentally, I spoke about penicillin for two reasons. First of all, it was a drug that completely revolutionized the treatment of bacterial infections since it destroyed the cell wall of the bacteria. It was a new technology out of left field that turned treatment of bacterial infections on its head! Sulfa on the other hand, merely slowed down the growth of the bacteria, and really needed the assistance of the immune system to finish off the bacteria. Current anti-viral drugs act like sulfa and we act like penicillin in that respect.

Thanks for your time in clarifying the above. --Dave